Health Canada
- Status: approved
OGIVRI (TRASTUZUMAB-DKST) regulatory status in Canada.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. Health Canada has authorised it.
MYLAN GMBH is the originator. The local marketing authorisation holder may differ — check the official source linked above.